Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Biological functions and metabolism of oleoylethanolamide.

Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, Destaillats F.

Lipids. 2008 Oct;43(10):887-94. doi: 10.1007/s11745-008-3217-y. Epub 2008 Aug 13. Review.

PMID:
18704536
2.

Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).

Guzmán M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D.

J Biol Chem. 2004 Jul 2;279(27):27849-54. Epub 2004 Apr 26.

3.

Regulation of food intake by oleoylethanolamide.

Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D.

Cell Mol Life Sci. 2005 Mar;62(6):708-16. Review.

4.

Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.

Suardíaz M, Estivill-Torrús G, Goicoechea C, Bilbao A, Rodríguez de Fonseca F.

Pain. 2007 Dec 15;133(1-3):99-110. Epub 2007 Apr 20.

PMID:
17449181
5.

The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice.

Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA.

Neurogastroenterol Motil. 2009 Apr;21(4):420-9. doi: 10.1111/j.1365-2982.2008.01248.x. Epub 2008 Dec 31.

6.

Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.

Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D.

Neuropharmacology. 2005 Jun;48(8):1147-53. Epub 2005 Apr 21.

PMID:
15910890
7.

Oleic acid-derived oleoylethanolamide: A nutritional science perspective.

Bowen KJ, Kris-Etherton PM, Shearer GC, West SG, Reddivari L, Jones PJH.

Prog Lipid Res. 2017 Jul;67:1-15. doi: 10.1016/j.plipres.2017.04.001. Epub 2017 Apr 5. Review.

PMID:
28389247
8.

The satiety factor oleoylethanolamide impacts hepatic lipid and glucose metabolism in goldfish.

Gómez-Boronat M, Velasco C, Isorna E, De Pedro N, Delgado MJ, Soengas JL.

J Comp Physiol B. 2016 Dec;186(8):1009-1021. Epub 2016 Jun 8.

PMID:
27277972
9.

Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells.

Martínez de Ubago M, García-Oya I, Pérez-Pérez A, Canfrán-Duque A, Quintana-Portillo R, Rodríguez de Fonseca F, González-Yanes C, Sánchez-Margalet V.

Biochim Biophys Acta. 2009 Aug;1791(8):740-5. doi: 10.1016/j.bbalip.2009.03.014. Epub 2009 Apr 5.

PMID:
19345745
10.

Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo.

Almási R, Szoke E, Bölcskei K, Varga A, Riedl Z, Sándor Z, Szolcsányi J, Petho G.

Life Sci. 2008 Mar 12;82(11-12):644-51. doi: 10.1016/j.lfs.2007.12.022. Epub 2008 Jan 12.

PMID:
18261748
11.

Role of endocannabinoids and their analogues in obesity and eating disorders.

Gaetani S, Kaye WH, Cuomo V, Piomelli D.

Eat Weight Disord. 2008 Sep;13(3):e42-8. Erratum in: Eat Weight Disord. 2011 Mar;16(1):e72.

PMID:
19011363
12.

'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors.

Ho WS, Barrett DA, Randall MD.

Br J Pharmacol. 2008 Nov;155(6):837-46. doi: 10.1038/bjp.2008.324. Epub 2008 Aug 11.

13.

Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα.

Karwad MA, Macpherson T, Wang B, Theophilidou E, Sarmad S, Barrett DA, Larvin M, Wright KL, Lund JN, O'Sullivan SE.

FASEB J. 2017 Feb;31(2):469-481. doi: 10.1096/fj.201500132. Epub 2016 Sep 13.

PMID:
27623929
14.

Brain molecules and appetite: the case of oleoylethanolamide.

Sarro-Ramírez A, Sánchez-López D, Tejeda-Padrón A, Frías C, Zaldívar-Rae J, Murillo-Rodríguez E.

Cent Nerv Syst Agents Med Chem. 2013 Mar;13(1):88-91. Review.

PMID:
23464987
15.

Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance.

Borrelli F, Izzo AA.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):33-49. doi: 10.1016/j.beem.2008.10.003. Review.

PMID:
19285259
16.

Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.

Li L, Li L, Chen L, Lin X, Xu Y, Ren J, Fu J, Qiu Y.

J Pharmacol Sci. 2015 Mar;127(3):244-50. doi: 10.1016/j.jphs.2014.12.001. Epub 2014 Dec 9.

17.

Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.

Chen L, Li L, Chen J, Li L, Zheng Z, Ren J, Qiu Y.

Oncotarget. 2015 Dec 15;6(40):42530-40. doi: 10.18632/oncotarget.6466.

18.

Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat.

Suárez J, Rivera P, Arrabal S, Crespillo A, Serrano A, Baixeras E, Pavón FJ, Cifuentes M, Nogueiras R, Ballesteros J, Dieguez C, Rodríguez de Fonseca F.

Dis Model Mech. 2014 Jan;7(1):129-41. doi: 10.1242/dmm.013110. Epub 2013 Oct 23.

19.

Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.

Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D.

J Pharmacol Exp Ther. 2005 Apr;313(1):352-8. Epub 2004 Dec 3.

20.

Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome.

Igarashi M, Narayanaswami V, Kimonis V, Galassetti PM, Oveisi F, Jung KM, Piomelli D.

Pharmacol Res. 2017 Mar;117:75-81. doi: 10.1016/j.phrs.2016.12.024. Epub 2016 Dec 19.

PMID:
28007570

Supplemental Content

Support Center